Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01400919 · ClinicalTrials.gov registry record · NA
DURABILITY™ Iliac Study
A NA study, sponsored by Medtronic Endovascular.
- Completed
- Registry status
- NA
- Development phase
- 75
- Enrollment target
NCT01400919 is a NA study that has completed, run by Medtronic Endovascular. The registered enrollment target is 75 participants.
The verdict
NCT01400919, a NA study, has completed, sponsored by Medtronic Endovascular.
- COMPLETED
- Registry status
- NA
- Development phase
- 75 participants
- Enrollment target
Study Summary
The DURABILITY Iliac study is a prospective, multi-center, non-randomized study confirming the safety and effectiveness of stenting using the Protégé® EverFlex™ and Protégé® GPS™ Self-Expanding Stent Systems for the treatment of atherosclerotic lesions in the common and/or external iliac arteries.
Interventions
- DEVICE Protégé® EverFlex™ Self-Expanding Stent System, and Protégé® GPS™ Self-Expanding Stent System.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2011-07 |
| Est. Completion | 2016-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01400919
The ClinicalTrials.gov registry entry for NCT01400919 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Endovascular, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Protégé® EverFlex™ Self-Expanding Stent System, and Protégé® GPS™ Self-Expanding Stent System. is the first listed.
NCT01400919 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01400919 about?
NCT01400919 is a clinical study titled "DURABILITY™ Iliac Study". The DURABILITY Iliac study is a prospective, multi-center, non-randomized study confirming the safety and effectiveness of stenting using the Protégé® EverFlex™ and Protégé® GPS™ Self-Expanding Stent Systems for the treatment of atherosclerotic lesions in the common and/or external iliac arteries.
What is the current status of trial NCT01400919?
This trial is currently completed. It is a NA study. The enrollment target is 75 participants. The study started on 2011-07. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01400919?
The interventions under investigation include: Protégé® EverFlex™ Self-Expanding Stent System, and Protégé® GPS™ Self-Expanding Stent System. (DEVICE).
Who is sponsoring clinical trial NCT01400919?
This trial is sponsored by Medtronic Endovascular, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.